# A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

> **NCT03825731** · EARLY_PHASE1 · UNKNOWN · sponsor: **Hebei Yanda Ludaopei Hospital** · enrollment: 20 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** GC022

## Key facts

- **NCT ID:** NCT03825731
- **Lead sponsor:** Hebei Yanda Ludaopei Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-17
- **Primary completion:** 2019-09-16
- **Final completion:** 2019-09-16
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03825731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03825731, "A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT03825731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*